Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration.
Identifieur interne : 000700 ( PubMed/Curation ); précédent : 000699; suivant : 000701Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration.
Auteurs : Vincent Daien [France] ; Vuong Nguyen [Australie] ; Rohan W. Essex ; Nigel Morlet [Australie] ; Daniel Barthelmes [Suisse] ; Mark C. Gillies [Australie]Source :
- Ophthalmology [ 1549-4713 ] ; 2017.
Abstract
To assess the incidence, cumulative rate, and long-term outcomes of infectious and noninfectious endophthalmitis after intravitreal injections (IVTs) of anti-vascular endothelial growth factor (VEGF) agents.
DOI: 10.1016/j.ophtha.2017.07.005
PubMed: 28801117
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000703
Links to Exploration step
pubmed:28801117Curation
No country items
Rohan W. Essex<affiliation><nlm:affiliation>Academic Unit of Ophthalmology, Australian National University, Acton, Australian Capital Territory.</nlm:affiliation><wicri:noCountry code="subField">Australian Capital Territory</wicri:noCountry></affiliation>Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration.</title><author><name sortKey="Daien, Vincent" sort="Daien, Vincent" uniqKey="Daien V" first="Vincent" last="Daien">Vincent Daien</name><affiliation wicri:level="1"><nlm:affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales; Department of Ophthalmology, Gui De Chauliac Hospital, Montpellier, France; Inserm, U1061, Montpellier, France. Electronic address: vincent.daien@sydney.edu.au.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales; Department of Ophthalmology, Gui De Chauliac Hospital, Montpellier, France; Inserm, U1061, Montpellier</wicri:regionArea></affiliation></author><author><name sortKey="Nguyen, Vuong" sort="Nguyen, Vuong" uniqKey="Nguyen V" first="Vuong" last="Nguyen">Vuong Nguyen</name><affiliation wicri:level="2"><nlm:affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales.</nlm:affiliation><country>Australie</country><placeName><region type="state">Nouvelle-Galles du Sud</region></placeName><wicri:cityArea>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney</wicri:cityArea></affiliation></author><author><name sortKey="Essex, Rohan W" sort="Essex, Rohan W" uniqKey="Essex R" first="Rohan W" last="Essex">Rohan W. Essex</name><affiliation><nlm:affiliation>Academic Unit of Ophthalmology, Australian National University, Acton, Australian Capital Territory.</nlm:affiliation><wicri:noCountry code="subField">Australian Capital Territory</wicri:noCountry></affiliation></author><author><name sortKey="Morlet, Nigel" sort="Morlet, Nigel" uniqKey="Morlet N" first="Nigel" last="Morlet">Nigel Morlet</name><affiliation wicri:level="2"><nlm:affiliation>Department of Population Health, University of Western Australia, Perth, Western Australia.</nlm:affiliation><country>Australie</country><placeName><region type="state">Australie-Occidentale</region></placeName><wicri:cityArea>Department of Population Health, University of Western Australia, Perth</wicri:cityArea></affiliation></author><author><name sortKey="Barthelmes, Daniel" sort="Barthelmes, Daniel" uniqKey="Barthelmes D" first="Daniel" last="Barthelmes">Daniel Barthelmes</name><affiliation wicri:level="1"><nlm:affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales; Department of Ophthalmology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales; Department of Ophthalmology, University Hospital Zurich, University of Zurich, Zurich</wicri:regionArea></affiliation></author><author><name sortKey="Gillies, Mark C" sort="Gillies, Mark C" uniqKey="Gillies M" first="Mark C" last="Gillies">Mark C. Gillies</name><affiliation wicri:level="2"><nlm:affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales.</nlm:affiliation><country>Australie</country><placeName><region type="state">Nouvelle-Galles du Sud</region></placeName><wicri:cityArea>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28801117</idno><idno type="pmid">28801117</idno><idno type="doi">10.1016/j.ophtha.2017.07.005</idno><idno type="wicri:Area/PubMed/Corpus">000703</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000703</idno><idno type="wicri:Area/PubMed/Curation">000700</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000700</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration.</title><author><name sortKey="Daien, Vincent" sort="Daien, Vincent" uniqKey="Daien V" first="Vincent" last="Daien">Vincent Daien</name><affiliation wicri:level="1"><nlm:affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales; Department of Ophthalmology, Gui De Chauliac Hospital, Montpellier, France; Inserm, U1061, Montpellier, France. Electronic address: vincent.daien@sydney.edu.au.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales; Department of Ophthalmology, Gui De Chauliac Hospital, Montpellier, France; Inserm, U1061, Montpellier</wicri:regionArea></affiliation></author><author><name sortKey="Nguyen, Vuong" sort="Nguyen, Vuong" uniqKey="Nguyen V" first="Vuong" last="Nguyen">Vuong Nguyen</name><affiliation wicri:level="2"><nlm:affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales.</nlm:affiliation><country>Australie</country><placeName><region type="state">Nouvelle-Galles du Sud</region></placeName><wicri:cityArea>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney</wicri:cityArea></affiliation></author><author><name sortKey="Essex, Rohan W" sort="Essex, Rohan W" uniqKey="Essex R" first="Rohan W" last="Essex">Rohan W. Essex</name><affiliation><nlm:affiliation>Academic Unit of Ophthalmology, Australian National University, Acton, Australian Capital Territory.</nlm:affiliation><wicri:noCountry code="subField">Australian Capital Territory</wicri:noCountry></affiliation></author><author><name sortKey="Morlet, Nigel" sort="Morlet, Nigel" uniqKey="Morlet N" first="Nigel" last="Morlet">Nigel Morlet</name><affiliation wicri:level="2"><nlm:affiliation>Department of Population Health, University of Western Australia, Perth, Western Australia.</nlm:affiliation><country>Australie</country><placeName><region type="state">Australie-Occidentale</region></placeName><wicri:cityArea>Department of Population Health, University of Western Australia, Perth</wicri:cityArea></affiliation></author><author><name sortKey="Barthelmes, Daniel" sort="Barthelmes, Daniel" uniqKey="Barthelmes D" first="Daniel" last="Barthelmes">Daniel Barthelmes</name><affiliation wicri:level="1"><nlm:affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales; Department of Ophthalmology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales; Department of Ophthalmology, University Hospital Zurich, University of Zurich, Zurich</wicri:regionArea></affiliation></author><author><name sortKey="Gillies, Mark C" sort="Gillies, Mark C" uniqKey="Gillies M" first="Mark C" last="Gillies">Mark C. Gillies</name><affiliation wicri:level="2"><nlm:affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales.</nlm:affiliation><country>Australie</country><placeName><region type="state">Nouvelle-Galles du Sud</region></placeName><wicri:cityArea>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney</wicri:cityArea></affiliation></author></analytic><series><title level="j">Ophthalmology</title><idno type="eISSN">1549-4713</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To assess the incidence, cumulative rate, and long-term outcomes of infectious and noninfectious endophthalmitis after intravitreal injections (IVTs) of anti-vascular endothelial growth factor (VEGF) agents.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">28801117</PMID><DateCreated><Year>2017</Year><Month>08</Month><Day>12</Day></DateCreated><DateRevised><Year>2017</Year><Month>08</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1549-4713</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2017</Year><Month>Aug</Month><Day>08</Day></PubDate></JournalIssue><Title>Ophthalmology</Title><ISOAbbreviation>Ophthalmology</ISOAbbreviation></Journal><ArticleTitle>Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0161-6420(17)30747-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ophtha.2017.07.005</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To assess the incidence, cumulative rate, and long-term outcomes of infectious and noninfectious endophthalmitis after intravitreal injections (IVTs) of anti-vascular endothelial growth factor (VEGF) agents.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Database study, prospectively designed.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Treatment-naïve eyes with neovascular age-related macular degeneration (nAMD) tracked by the Fight Retinal Blindness! (FRB!) registry that commenced anti-VEGF therapy between January 1, 2006, and November 30, 2016.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Cumulative rate of endophthalmitis and survival curves were measured using Cox-proportional hazards models. Locally weighted scatterplot smoothing curves were used to display visual acuity (VA).</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Incidence and cumulative rate of endophthalmitis, and change in VA 12 months after endophthalmitis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Infectious endophthalmitis developed in 18 of 88 150 injections (1/4897 injections [0.020%]; 95% confidence interval [CI], 0.012-0.032) with no difference found between types of anti-VEGF medications (P = 0.896). The cumulative rate of infectious endophthalmitis per patient was 0.055%, 0.183%, 0.360%, 0.360%, 0.555%, and 0.843% after 10, 20, 30, 40, 50, and 60 IVTs, respectively. However, the "risk" of infectious endophthalmitis did not increase with each successive injection (P = 0.202). Noninfectious endophthalmitis developed in 11 of 88 150 injections (1/8013 injections [0.012%]; 95% CI, 0.006-0.022). The cumulative rate of noninfectious endophthalmitis per patient was 0.087% and 0.228% after 10 and 20 IVTs, respectively, and then remained stable up to 60 IVTs. The incidence of noninfectious endophthalmitis was higher for bevacizumab (8/9931, 0.081%) compared with ranibizumab (3/54 776, 0.005%; P = 0.005) and aflibercept (0/23 425; P = 0.016), and no differences were observed between ranibizumab and aflibercept (P = 1.0). The 12-month VA in infectious and noninfectious endophthalmitis was within ±2 lines of before endophthalmitis in 53% and 75% of eyes, respectively; a loss >2 lines was observed in 31% and 25% of eyes, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The incidences of infectious and noninfectious endophthalmitis after IVT were low, and the risk did not increase with each successive injection. We found higher rates of noninfectious endophthalmitis with bevacizumab compared with ranibizumab or aflibercept. Three quarters of cases with infectious and two thirds of cases with noninfectious endophthalmitis retained vision within 10 letters of the pre-endophthalmitis level.</AbstractText><CopyrightInformation>Copyright © 2017 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Daien</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales; Department of Ophthalmology, Gui De Chauliac Hospital, Montpellier, France; Inserm, U1061, Montpellier, France. Electronic address: vincent.daien@sydney.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Vuong</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Essex</LastName><ForeName>Rohan W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Academic Unit of Ophthalmology, Australian National University, Acton, Australian Capital Territory.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morlet</LastName><ForeName>Nigel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Population Health, University of Western Australia, Perth, Western Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barthelmes</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales; Department of Ophthalmology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gillies</LastName><ForeName>Mark C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Fight Retinal Blindness! Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>08</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ophthalmology</MedlineTA><NlmUniqueID>7802443</NlmUniqueID><ISSNLinking>0161-6420</ISSNLinking></MedlineJournalInfo><InvestigatorList><Investigator ValidYN="Y"><LastName>Gillies</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunt</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Essex</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dayajeewa</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunyor</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fraser-Bell</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Younan</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fung</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guymer</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Louis</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chan</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cass</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guymer</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harper</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Day</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daniell</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Field</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chow</LastName><ForeName>L P</ForeName><Initials>LP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barthelmes</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chow</LastName><ForeName>L P</ForeName><Initials>LP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cohn</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Young</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lal</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Young</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrier</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barnes</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vincent</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manning</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lake</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Phillips</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perks</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>J Y</ForeName><Initials>JY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Landers</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Niladri</LastName></Investigator><Investigator ValidYN="Y"><LastName>Banerjee</LastName><ForeName>Gayatri</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swamy</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Windle</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dunlop</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tang</LastName><ForeName>K C</ForeName><Initials>KC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cohn</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cohn</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>McLean</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amini</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunt</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>McAllister</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Squirrell</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ng</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Louis</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gillies</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hinchcliffe</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barry</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Louis</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ah-Chan</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steiner</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chow</LastName><ForeName>L P</ForeName><Initials>LP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cohn</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morgan</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swamy</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Game</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Young</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murray</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>03</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>06</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>07</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28801117</ArticleId><ArticleId IdType="pii">S0161-6420(17)30747-9</ArticleId><ArticleId IdType="doi">10.1016/j.ophtha.2017.07.005</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000700 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000700 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:28801117
|texte= Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:28801117" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |